Daniel Pilsgaard Henriksen1,2, Jesper Rømhild Davidsen3, Christian B Laursen3, Anders Christiansen3, Per Damkier4,5, Jesper Hallas4,6, Anton Pottegård6. 1. Department of Respiratory Medicine, Odense University Hospital, B Winsløwsvej 19, 2, 5000, Odense C, Denmark. dphenriksen@health.sdu.dk. 2. Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense, Denmark. dphenriksen@health.sdu.dk. 3. Department of Respiratory Medicine, Odense University Hospital, B Winsløwsvej 19, 2, 5000, Odense C, Denmark. 4. Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense, Denmark. 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 6. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Abstract
PURPOSE: Montelukast is a leukotriene receptor antagonist used in asthma and rhinitis treatment. Despite being marketed nearly two decades ago, little is known about its utilisation pattern. METHODS: Using the Danish National Prescription Registry, we identified subjects filling a montelukast prescription between 1998 and 2017. Using descriptive statistics, we reported the development in incidence, and prevalence, as well as a measure of treatment duration, and concomitant use of asthma- or anti-allergic therapy. RESULTS: We identified 147,247 individuals filling 1,327,489 montelukast prescriptions. A total of 54,349 users (37%) filled only one montelukast prescription. The prevalence increased from 0.9/1000 persons in 1998 to 3.3/1000 persons in 2016. The rate of new users reached its maximum of 2.1/1000 person-years in 2009. Among new montelukast users, 28% were still users after 1 year. Among all montelukast initiators, 60% filled at least one prescription of short-acting beta-2-agonists (SABA) up to a year prior to montelukast initiation, and 49% filled a prescription of inhaled corticosteroids (ICS). Only 0.8% (n = 1148) of all individuals initiated montelukast without a redeemed prescription of short- or long-term inhalation therapy, systemic antihistamines, or nasal topical anti-allergic treatment. CONCLUSIONS: The usage of montelukast has increased over threefold since its market entry in 1998, mainly driven by an increased number of prevalent users. The majority of individuals who initiated montelukast filled a prescription of SABA up to a year prior to montelukast initiation, whereas almost half filled a prescription of ICS.
PURPOSE:Montelukast is a leukotriene receptor antagonist used in asthma and rhinitis treatment. Despite being marketed nearly two decades ago, little is known about its utilisation pattern. METHODS: Using the Danish National Prescription Registry, we identified subjects filling a montelukast prescription between 1998 and 2017. Using descriptive statistics, we reported the development in incidence, and prevalence, as well as a measure of treatment duration, and concomitant use of asthma- or anti-allergic therapy. RESULTS: We identified 147,247 individuals filling 1,327,489 montelukast prescriptions. A total of 54,349 users (37%) filled only one montelukast prescription. The prevalence increased from 0.9/1000 persons in 1998 to 3.3/1000 persons in 2016. The rate of new users reached its maximum of 2.1/1000 person-years in 2009. Among new montelukast users, 28% were still users after 1 year. Among all montelukast initiators, 60% filled at least one prescription of short-acting beta-2-agonists (SABA) up to a year prior to montelukast initiation, and 49% filled a prescription of inhaled corticosteroids (ICS). Only 0.8% (n = 1148) of all individuals initiated montelukast without a redeemed prescription of short- or long-term inhalation therapy, systemic antihistamines, or nasal topical anti-allergic treatment. CONCLUSIONS: The usage of montelukast has increased over threefold since its market entry in 1998, mainly driven by an increased number of prevalent users. The majority of individuals who initiated montelukast filled a prescription of SABA up to a year prior to montelukast initiation, whereas almost half filled a prescription of ICS.
Authors: Iben Rix; Kåre Håkansson; Christian Grønhøj Larsen; Martin Frendø; Christian von Buchwald Journal: Am J Rhinol Allergy Date: 2015 May-Jun Impact factor: 2.467
Authors: Mary Elizabeth Bollinger; Gregory B Diette; Chun-Lan Chang; Judith J Stephenson; Shiva G Sajjan; Tao Fan; Felicia C Allen-Ramey Journal: Clin Ther Date: 2010-06 Impact factor: 3.393
Authors: Surrey M Walton; Glen T Schumock; Ky-Van Lee; G Caleb Alexander; David Meltzer; Randall S Stafford Journal: Pharmacotherapy Date: 2008-12 Impact factor: 4.705
Authors: Maurizio Sessa; Annamaria Mascolo; Bruno D'Agostino; Antonio Casciotta; Vincenzo D'Agostino; Fausto De Michele; Mario Polverino; Giuseppe Spaziano; Mikkel Porsborg Andersen; Kristian Kragholm; Francesco Rossi; Christian Torp-Pedersen; Annalisa Capuano Journal: Front Pharmacol Date: 2018-08-02 Impact factor: 5.810